Product image of Mucosolvan Perlonguets (Ambroxol Hydrochloride) supplied by GNH India

Mucosolvan Perlonguets

Active Ingredient:
Ambroxol Hydrochloride
Origin:
EU

Mucosolvan Perlonguets (Ambroxol Hydrochloride)

Ambroxol Hydrochloride, the active ingredient in Mucosolvan Perlonguets, is a mucolytic agent presented as an oral formulation for oral use. It helps to thin and loosen thick bronchial secretions, facilitating expectoration in patients with respiratory conditions that produce viscous sputum.

GNH India supplies Mucosolvan Perlonguets as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Opella Healthcare Portugal Unipessoal Lda.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mucosolvan Perlonguets, containing ambroxol hydrochloride, is used in the management of respiratory disorders characterized by excessive or thick mucus production.

  • Acute bronchitis with productive cough: improves clearance of sputum and reduces cough duration.
  • Chronic obstructive pulmonary disease (COPD) with mucus hypersecretion: aids in reducing sputum viscosity and facilitates expectoration.
  • Other respiratory conditions with thick, viscous sputum: enhances mucociliary clearance and eases breathing.

How It Works

  • Ambroxol hydrochloride stimulates serous cells of the bronchial epithelium to increase surfactant secretion and disrupts the glycoprotein matrix of mucus, lowering its viscosity. The resulting thinner mucus is more readily moved by ciliary action, leading to improved mucociliary clearance from the airways.

Side Effects

Ambroxol may be associated with a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects

  • Altered taste sensation: transient metallic or bitter taste.
  • Nausea: mild to moderate discomfort in the stomach.
  • Diarrhoea: loose stools occurring shortly after administration.
  • Stomach discomfort: abdominal pain or dyspepsia.
  • Skin rash: mild erythematous eruption.
  • Headache: occasional mild headache.

Serious or Rare Side Effects

  • Allergic reactions: urticaria, pruritus, or angioedema.
  • Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Hepatic enzyme elevation: potential liver function abnormalities.
  • Eosinophilia: increased eosinophil count in blood.
  • Anaphylaxis: rare but life‑threatening hypersensitivity.
  • Respiratory distress: bronchospasm in susceptible individuals.

Precautions & Warnings

When prescribing or dispensing Mucosolvan Perlonguets, consider the following precautions.

  • Renal impairment: use with caution in patients with severe kidney disease.
  • Hepatic disease: monitor liver function in patients with pre‑existing liver conditions.
  • Asthma: may provoke bronchospasm; observe closely in asthmatic patients.
  • Pregnancy and lactation: safety not established; evaluate risk‑benefit before use.
  • Drug interactions: review concomitant medications for potential interactions.
  • Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Avoid Interactions

Ambroxol can interact with several medicines; awareness of the interaction level helps guide clinical decisions.

Major Interactions (Avoid)

  • Anticholinergic agents: may diminish mucolytic efficacy.
  • Cytotoxic chemotherapy: increased risk of pulmonary toxicity.
  • Beta‑agonist bronchodilators: potential additive bronchospasm.

Moderate Interactions (Monitor Closely)

  • Macrolide antibiotics: may raise ambroxol plasma concentrations.
  • Warfarin: monitor INR as ambroxol can affect coagulation parameters.
  • Theophylline: observe for altered respiratory response or side‑effect profile.

Frequently Asked Questions

Mucosolvan Perlonguets is indicated for the treatment of respiratory conditions that involve thick, viscous mucus, such as acute bronchitis with productive cough, chronic obstructive pulmonary disease (COPD) with mucus hypersecretion, and other disorders where facilitating sputum clearance improves breathing.

Ambroxol hydrochloride increases surfactant production by bronchial serous cells and breaks down the molecular bonds within mucus glycoproteins. This reduces mucus viscosity and enhances ciliary activity, resulting in more efficient mucociliary clearance from the airways.

The appropriate dose of Mucosolvan Perlonguets is determined by the prescribing healthcare professional based on the patient’s age, clinical condition, and response to therapy. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Safety data for ambroxol hydrochloride in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ambroxol (Mucosolvan Perlonguets) and acetylcysteine act as mucolytics, but ambroxol also stimulates surfactant secretion and may have a more pronounced effect on reducing mucus viscosity. Choice of agent depends on clinical judgment, patient tolerance, and specific therapeutic goals.

Store Mucosolvan Perlonguets at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed when not in use.

Mucosolvan Perlonguets is taken orally, usually with a glass of water. The tablet (or oral formulation) should be swallowed whole unless otherwise instructed by a healthcare professional.

Serious adverse reactions, although rare, include severe allergic responses such as anaphylaxis, angioedema, Stevens‑Johnson syndrome, and significant hepatic enzyme elevations. Immediate medical attention is required if any of these events occur.

Patients with known hypersensitivity to ambroxol hydrochloride or any excipients in the formulation should avoid the product. Caution is also advised for individuals with severe renal or hepatic impairment, uncontrolled asthma, or those taking medications that have major interaction potential.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ambroxol Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT